



Original Investigation | Cardiology

Use of Cardiopulmonary Exercise Testing to Evaluate Long COVID-19 Symptoms in Adults

A Systematic Review and Meta-analysis

Matthew S. Durstenfeld, MD, MAS; Kaiwen Sun, MD; Peggy Tahir, MLIS, MA; Michael J. Peluso, MD, MHS, MPhil, DTMH; Steven G. Deeks, MD; Mandar A. Aras, MD, PhD; Donald J. Grandis, MD; Carlin S. Long, MD; Alexis Beatty, MD; Priscilla Y. Hsue, MD

Abstract

IMPORTANCE Reduced exercise capacity is commonly reported among individuals with COVID-19 symptoms more than 3 months after SARS-CoV-2 infection (long COVID-19 [LC]). Cardiopulmonary exercise testing (CPET) is the criterion standard to measure exercise capacity and identify patterns of exertional intolerance.

OBJECTIVES To estimate the difference in exercise capacity among individuals with and without LC symptoms and characterize physiological patterns of limitations to elucidate possible mechanisms of LC.

DATA SOURCES A search of PubMed, EMBASE, Web of Science, preprint servers, conference abstracts, and cited references was performed on December 20, 2021, and again on May 24, 2022. A preprint search of medrxiv.org, biorxiv.org, and researchsquare.com was performed on June 9, 2022.

STUDY SELECTION Studies of adults with SARS-CoV-2 infection more than 3 months earlier that included CPET-measured peak oxygen consumption ($\dot{V}O_2$) were screened independently by 2 blinded reviewers; 72 (2%) were selected for full-text review, and 35 (1%) met the inclusion criteria. An additional 3 studies were identified from preprint servers.

DATA EXTRACTION AND SYNTHESIS Data extraction was performed by 2 independent reviewers according to the PRISMA reporting guideline. Data were pooled using random-effects models.

MAIN OUTCOMES AND MEASURES Difference in peak $\dot{V}O_2$ (in mL/kg/min) among individuals with and without persistent COVID-19 symptoms more than 3 months after SARS-CoV-2 infection.

RESULTS A total of 38 studies were identified that performed CPET on 2160 individuals 3 to 18 months after SARS-CoV-2 infection, including 1228 with symptoms consistent with LC. Most studies were case series of individuals with LC or cross-sectional assessments within posthospitalization cohorts. Based on a meta-analysis of 9 studies including 464 individuals with LC symptoms and 359 without symptoms, the mean peak $\dot{V}O_2$ was -4.9 (95% CI, -6.4 to -3.4) mL/kg/min among those with symptoms with a low degree of certainty. Deconditioning and peripheral limitations (abnormal oxygen extraction) were common, but dysfunctional breathing and chronotropic incompetence were also described. The existing literature was limited by small sample sizes, selection bias, confounding, and varying symptom definitions and CPET interpretations, resulting in high risk of bias and heterogeneity.

(continued)

Key Points

Question Is exercise capacity reduced more than 3 months after SARS-CoV-2 infection among those with long COVID-19 (LC) symptoms compared with recovered individuals without symptoms, and what patterns of limitations on cardiopulmonary exercise testing (CPET) are common?

Findings In this systematic review and meta-analysis of 38 studies comprising 2160 participants, exercise capacity was reduced by 4.9 mL/kg/min among individuals with symptoms consistent with LC compared with individuals without symptoms more than 3 months after SARS-CoV-2 infection. Findings among individuals with exertional intolerance suggest that deconditioning, dysfunctional breathing, chronotropic incompetence, and abnormal peripheral oxygen extraction and/or use may contribute to reduced exercise capacity.

Meaning These findings suggest that CPET may provide insight into the mechanisms for reduced exercise capacity among individuals with LC.

+ [Multimedia](#)

+ [Supplemental content](#)

Author affiliations and article information are listed at the end of this article.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

Abstract (continued)

CONCLUSIONS AND RELEVANCE The findings of this systematic review and meta-analysis study suggest that exercise capacity was reduced more than 3 months after SARS-CoV-2 infection among individuals with symptoms consistent with LC compared with individuals without LC symptoms, with low confidence. Potential mechanisms for exertional intolerance other than deconditioning include altered autonomic function (eg, chronotropic incompetence, dysfunctional breathing), endothelial dysfunction, and muscular or mitochondrial pathology.

JAMA Network Open. 2022;5(10):e2236057. doi:10.1001/jamanetworkopen.2022.36057

Introduction

After SARS-CoV-2 infection, a substantial proportion of survivors with long COVID-19 (LC) experience persistent cardiopulmonary symptoms and exercise intolerance. Long COVID-19 may occur in 3% to 30% of individuals after SARS-CoV-2 infection,¹⁻⁵ including nonhospitalized and vaccinated individuals,^{6,7} and can persist for at least 12 months.⁸

Cardiopulmonary exercise testing (CPET) is the criterion standard for measuring exercise capacity and aiding in the differential diagnosis of exercise limitations.⁹⁻¹¹ After measuring resting cardiopulmonary parameters, participants exercise on a cycle ergometer or a treadmill with measurement of gas exchange and cardiopulmonary monitoring. Measuring oxygen consumption ($\dot{V}O_2$) allows for objective and reproducible determination of exercise capacity, determination of anaerobic threshold, and classification of limitations. Research CPET has provided insight into persistent symptoms after SARS,¹² dyspnea in people living with HIV,¹³ and exercise intolerance in myalgic encephalitis and/or chronic fatigue syndrome (ME/CFS).¹⁴⁻¹⁶ Clinically, CPET is useful diagnostically for unexplained dyspnea⁹ and prognostically in heart failure,¹⁷ lung disease,⁹ and preoperative evaluations.¹⁸

Case series suggest that SARS-CoV-2 infection is associated with reduced exercise capacity.^{19,20} A prior narrative review of 11 studies including 581 patients²¹ suggested that deconditioning was a major cause of reduced exercise capacity after COVID-19 hospitalization, with literature limited by confounding and lack of controls; however, to our knowledge, no systematic review on the role of CPET in LC has been published. Whether exercise intolerance persists and is associated with LC and the pathophysiology of exertional intolerance in LC, especially among individuals who are not hospitalized, is uncertain. Therefore, the objectives of this systematic review and meta-analysis were to address whether adults with persistent COVID-19 symptoms more than 3 months after SARS-CoV-2 infection²² have reduced exercise capacity on results of CPET compared with recovered individuals without symptoms and to identify potential causal pathways for the reduced exercise capacity after SARS-CoV-2 infection.

Methods

This systematic review and meta-analysis followed the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) reporting guideline and was registered prospectively on PROSPERO (CRD42021299842) before beginning the literature search. Because the study did not constitute human participants research, the University of California, San Francisco Institutional Review Board deemed it exempt from approval and waived informed consent.

We included studies that performed CPET measurement of peak $\dot{V}O_2$ among adults at least 3 months after SARS-CoV-2 infection, including case series (only symptomatic individuals), cohort studies (both symptomatic and recovered individuals), and baseline data from interventional studies. Of 3256 studies that were screened by title and abstract, we selected 72 (2%) for full-text review, (1%) of which met the inclusion criteria. Studies were excluded if participants were studied less than

3 months after infection or if they did not measure $\dot{V}O_2$. For the first objective, we only included studies that compared individuals with and without prevalent symptoms consistent with LC at the time of CPET; for the second objective, we included studies that classified participants with exercise limitations or explored specific mechanisms of limitations.

A comprehensive search was planned with a research librarian (P.T.) to identify all studies that used CPET to evaluate exercise capacity among adults more than 3 months after SARS-CoV-2 infection, including studies published since 2020, abstracts from conference proceedings, and indexed preprints without language restrictions. We searched PubMed, EMBASE, Web of Science, and references of included studies. We additionally searched medrxiv.org, biorxiv.org, and researchsquare.com for nonindexed preprints. The search strategy included terms and synonyms for the following: *COVID* or *SARS-CoV-2* along with *cardiopulmonary exercise test*, *CPET* or *CPX* or *CPEX*, *exercise capacity*, $\dot{V}O_2$, and *anaerobic threshold* tailored to each search engine (eTable 1 in the [Supplement](#)). Searches were conducted on December 20, 2021, and rerun on May 24, 2022; the preprint search was performed on June 9, 2022.

The searches were conducted by the research librarian (P.T.), with results downloaded and imported into a commercially available systemic reviews tool. After duplicates were automatically removed, 2 independent reviewers (M.S.D. and K.S.) screened each title and abstract using the systemic reviews tool and were blinded to each other's decision regarding full-text review. Studies for which both reviewers agreed to full-text review or disagreed after reconciliation discussion underwent full-text review. After full-text review and consensus discussion, there were no disagreements regarding study inclusion. Data extraction was performed independently, in duplicate, using REDCap (eMethods and eAppendix in the [Supplement](#)). Discrepancies were corrected by the first 2 authors (M.S.D. and K.S.) reviewing the full text together.

Quality was assessed independently by 2 reviewers (M.S.D. and K.S.) using Cochrane's Quality in Prognostic Studies tool²³ to assess study populations (inclusion criteria and control group), measurement quality (CPET exercise protocols, peak $\dot{V}O_2$ assessment, submaximal test results, and interpretation of CPET), outcome (symptom assessment), confounding, and statistical analysis and reporting, followed by discussion and tabulation of consensus results. The GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework was used to guide a consensus discussion for overall outcome assessment.²⁴

Owing to expected differences in study inclusion criteria, we used random-effects meta-analysis to estimate the mean difference in peak $\dot{V}O_2$ (in mL/kg/min) between those with and without prevalent LC symptoms as defined by each study using a restricted maximum likelihood variance estimator and Wald-type confidence intervals. For 2 studies that only reported median and IQR, the distance between the median and IQR upper and lower bounds were similar, so medians were taken as the mean and SD was estimated as the IQR divided by 1.35²⁵; subgroups were combined among studies only reporting results by groups.²⁵ Heterogeneity was assessed by examining forest plots, funnel plots, heterogeneity variance (τ^2 statistic), and inconsistency (I^2 statistic). Prespecified subgroup analyses by proportion hospitalized and time since infection were performed. Because of the small number of studies, tests for publication bias were not performed.

To synthesize findings for our second objective, we recorded the predominant explanatory finding for reduced exercise capacity, including deconditioning, ventilatory limitation, cardiac limitations, chronotropic incompetence, dysfunctional breathing/ventilatory inefficiency, or other limitations, and the number and proportion with each if reported. Meta-analysis was performed using Stata, version 17.1 (StataCorp LLC); 2-sided $P < .05$ indicated statistical significance.

Results

We identified 41 reports of 38 observational studies in which CPET was performed among 2160 individuals 3 to 18 months after SARS-CoV-2 infection,²⁶⁻⁶⁶ including 1228 individuals with symptoms consistent with LC. The studies included 33 published reports, 2 conference abstracts,

and 3 preprints (Figure 1). We identified 1 interventional study of cardiac rehabilitation⁶⁷ with baseline CPET reported in an included study.⁶⁸


Description of Included Studies

Table 1 lists study-level characteristics; eTable 2 and eTable 3 in the Supplement include the risk of bias assessments. Most studies (32 [84.2%]) were single-center case series of patients attending LC clinics or referred for clinical CPET (only symptomatic individuals) or cross-sectional assessments within COVID-19 recovery cohorts (with and without current symptoms). Most studies performed CPET 3 to 6 months after infection; only 1 study²⁶ investigated individuals more than 1 year after infection. Fourteen studies (36.8%)^{27,30,33,35,36,44,47,49,52,55,56,62,66,68} only included individuals who were hospitalized for acute infection (median, 70% [range, 0-100%] hospitalized), and 15 studies (39.5%)^{30,32,39-43,50,51,54,55,57,59,61,64} included individuals with prevalent symptoms at CPET (median, 95% [range, 38%-100%] symptomatic).

Exercise Capacity in Symptomatic Compared With Recovered Individuals

Nine studies^{26,29,31,33,37,38,44,45,47,58} included both individuals with prevalent symptoms (n = 464) and recovered individuals without prevalent symptoms (n = 359) (Table 2), with the risk of bias rated for each study in eTable 2 in the Supplement and overall quality in the eResults in the Supplement. Because definitions of LC and postacute sequelae of COVID-19 have evolved, studies used different symptom definitions, mostly based on prevalent symptoms at CPET (dyspnea, fatigue, or exertional intolerance). From meta-analyses of these 9 studies, mean peak $\dot{V}O_2$ is estimated to be -4.9 (95% CI, -6.4 to -3.4) mL/kg/min among individuals with symptoms ($P < .001$) (Figure 2). The I^2 statistic and funnel plot (eFigure 1 in the Supplement) suggest moderate heterogeneity. Two studies that did not find a statistically significant difference in symptom prevalence by reduced or preserved peak

Figure 1. Study Screening Diagram



Among 3523 references identified through our primary searches, we identified 72 studies for full-text review, of which 35 met the inclusion criteria. We additionally screened 3509 preprints and identified 7 for full-text review, resulting in a total of 38 studies included. CPET indicates cardiopulmonary exercise testing.

Table 1. Summary of Studies That Included Cardiopulmonary Exercise Testing (CPET) More Than 3 Months After SARS-CoV-2 Infection

Source	Report type	Study design, sampling, and/or recruitment	No. with SARS-CoV-2 infection	Hospitalized with infection, No./total No. (%)	Prevalent symptoms consistent with LC, No./total No. (%)	Time since infection, d ^a	Primary analytic comparisons
Abdallah et al, ⁴⁵ 2021	Research letter	Prospective cohort	63	25/63 (40)	34/49 (69)	125 (16)	Hospitalized vs nonhospitalized ⁴⁵ and fatigue vs no fatigue ^{58b} PASC vs controls
Alba et al, ⁴² 2021	Peer-reviewed published report	Retrospective cohort referred for CPET from LC clinic	18	3/18 (17)	18/18 (100)	257.5 (149-322)	Normal vs reduced exercise capacity
Ambrosino et al, ⁵⁵ 2022	Peer-reviewed published report	Pulmonary rehabilitation after severe COVID-19	36	36/36 (100)	36/36 (100)	NR	Persistent dyspnea vs no residual dyspnea LC vs no LC
Aparisi et al, ⁴⁷ 2021	Peer-reviewed published report	Prospective cohort post hospitalization	70	70/70 (100)	41/70 (59)	181 (42)	Vaccinated vs unvaccinated
Barbagelata et al, ³⁸ 2022	Peer-reviewed published report	Retrospective EHR review of individuals referred for clinical CPET	200	39/200 (20)	112/200 (56)	80 (21)	Peak $\dot{V}O_2$ >100% vs <100% of predicted levels Self-reported normal exercise capacity vs reduced exercise capacity vs controls
Blumberg et al, ²⁸ 2022	Preprint	Cross-sectional study	43	NR	NR	119 (24)	Change in CPET from 2-3 mo to 6 mo and vs controls Normal vs reduced exercise capacity
Borrego Rodriguez et al, ⁵⁹ 2021	Conference abstract	Nonhospitalized health care workers	57	0	57/57 (100)	>90	Fatty acid and lactate production in PASC vs published cohorts Ward vs ICU
Brown et al, ⁴⁴ 2022	Peer-reviewed published report	Prospective hospitalized cohort without ICU stay, myocardial injury, or comorbidities	40	40/40 (100)	20/40 (50)	Median, 106	Exercise ventilatory inefficiency vs efficiency
Cassar et al, ²⁷ 2021	Peer-reviewed published report	Prospective cohort after COVID hospitalization	42	42/42 (100)	NR (89% overall)	180 (180-204)	Cardiopulmonary symptoms vs no symptoms Change from CPET assessment 1 to 2
Clavario et al, ⁶⁸ 2021	Peer-reviewed published report	Prospective cohort after COVID hospitalization	200	200/200 (100)	160/200 (80)	107 (83-189)	Dysfunctional breathing vs normal breathing Descriptive
de Boer et al, ⁴⁰ 2022	Research letter	Retrospective case series of clinically referred for CPET	50	5/50 (10)	50/50 (100)	180 (120)	Impaired vs normal peak $\dot{V}O_2$
Debeaumont et al, ³⁰ 2021	Peer-reviewed published report	Retrospective case series of hospitalized patients with COVID-19 referred for CPET	23	23/23 (100)	23/23 (100)	180	Nonhospitalized vs hospitalized Descriptive
Dorelli et al, ⁴⁹ 2021	Research letter	Prospective cohort post hospitalization without comorbidities	28	28/28 (100)	NR	169 (28)	
Durstenfeld et al, ²⁶ 2022	Preprint	Prospective cohort without cardiovascular disease	39	7/39 (18)	23/39 (59)	525 (465-552)	
Evers et al, ⁵⁴ 2022	Peer-reviewed published report	Retrospective case series of patients referred for post-COVID-19 exercise limitation or dyspnea	30	21/30 (70)	30/30 (100)	Mean, 129	
Frésard et al, ⁵⁰ 2022	Peer-reviewed published report	Retrospective cohort of clinical CPET among patients referred for LC and persistent dyspnea	51	36/51 (71)	51/51 (100)	119 (89)	
Godinho and Freeman, ⁶¹ 2021	Conference abstract	Case series of nonhospitalized patients with persistent exercise limitations	9	0	9/9 (100)	Range, 180-360	
Jahn et al, ⁶² 2021	Research letter	Case series of patients with severe COVID-19 pneumonia attending posthospitalization pulmonary rehabilitation	35	35/35 (100)	NR	90	
Johnsen et al, ⁶³ 2021	Peer-reviewed published report	Case series of post-COVID-19 clinic referrals for CPET for symptoms	31	NR (60% overall)	NR (67% overall)	90	
Keirsten et al, ⁶³ 2021	Peer-reviewed published report	Case series of post-COVID-19 clinic referrals for CPET if initial test results not revealing	36	NR (8% overall)	NR	121 (77)	

(continued)

Table 1. Summary of Studies That Included Cardiopulmonary Exercise Testing (CPET) More Than 3 Months After SARS-CoV-2 Infection (continued)

Source	Report type	Study design, sampling, and/or recruitment	No. with SARS-CoV-2 infection	Hospitalized with infection, No./total No. (%)	Prevalent symptoms consistent with LC, No./total No. (%)	Time since infection, d ^a	Primary analytic comparisons
Ladlow et al, ³¹ 2022	Peer-reviewed published report	Prospective cohort of active military personnel	113	35/87 (31)	61/87 (70)	159 (7)	Comparisons by hospitalization and persistent symptoms compared with controls
Liu et al, ⁵² 2021	Peer-reviewed published report	Prospective posthospitalization cohort	41	41/41 (100)	NR	219 (11)	Pulmonary fibrosis vs no fibrosis
Mancini et al, ⁴³ 2021	Peer-reviewed published report	Case series of LC clinic referrals for CPET for symptoms	41	9/41 (22)	41/41 (100)	267 (99)	Descriptive
Margalit et al, ³⁷ 2022	Peer-reviewed published report	Nested case-control study within COVID recovery cohort	141	14/141 (10)	66/141 (47)	240 (75)	Fatigue vs no significant fatigue
Mohr et al, ⁴¹ 2021	Research letter	Case series of post-COVID-19 clinic referrals for CPET for dyspnea	10	6/10 (60)	10/10 (100)	Mean, 115	Descriptive
Motiejunaite et al, ⁴⁶ 2021	Research letter	Prospective cohort	114	104/114 (91)	58/114 (51)	90 (71-106)	DLCO >7.5 vs ≤7.5
Moulson et al, ⁵⁷ 2022	Peer-reviewed published report	Case series of young athletes referred for symptoms	21	NR	21/21 (100)	90 (63)	Young symptomatic athletes vs historical controls
Parikes et al, ⁶⁴ 2021	Preprint	Retrospective cohort of patients undergoing clinical CPET	12	9/12 (75)	12/12 (100)	182 (111)	Descriptive
Pleguezuelos et al, ⁵⁶ 2021	Peer-reviewed published report	Survivors of ARDS due to bilateral COVID-19 pneumonia requiring mechanical ventilation and tracheostomy	15	15/15 (100)	NR	NR	Mechanical efficiency, peak $\dot{V}O_2$, and power output in patients with COVID-19 vs 3 control groups
Ribeiro Baptista et al, ³⁶ 2022	Peer-reviewed published report	Prospective cohort with severe COVID-19 requiring hospitalization >7 d and oxygen	105	105/105 (100)	NR	90 d after discharge	Normal vs reduced exercise capacity
Rinaldo et al, ^{35,65} 2021	Research letter	Prospective cohort post hospitalization	75	75/75 (100)	39/75 (52)	97 (26)	Normal vs reduced exercise capacity
Romero-Ortuno et al, ³² 2022	Peer-reviewed published report	Cross-sectional study of symptomatic individuals within a prospective cohort	80	14/80 (17)	80/80 (100)	Median, 320 (range, 39-655)	Attaining >85% of predicted maximum heart rate
Singh et al, ³⁹ 2022	Peer-reviewed published report	Prospective cohort referred for CPET from LC clinic for unexplained exercise intolerance with negative initial findings of workup	10	1/10 (10)	10/10 (100)	330 (30)	LC vs controls
Sljørtten et al, ³³ 2021	Peer-reviewed published report	Multicenter prospective cohort post hospitalization	156	156/156 (100)	59/156 (38)	104 (90-139)	COVID-19 vs reference population norms and no dyspnea (mMRC, 0) vs dyspnea (mMRC, 1-4)
Szekely et al, ²⁹ 2021	Peer-reviewed published report	Prospective cohort of individuals evaluated at the emergency department for acute COVID-19	71	NR	48/71 (68)	91 (26)	COVID-19 vs control; asymptomatic vs symptomatic; severity of acute illness
Vannini et al, ⁶⁶ 2021	Research letter	Prospective cohort post hospitalization	41	41/41 (100)	29/41 (71)	180	Severity of acute illness and peak $\dot{V}O_2$ <80% vs ≥80%
von Gruenewaldt et al, ⁵¹ 2022	Peer-reviewed published report	Retrospective cohort of clinical CPET	20	8/20 (40)	20/20 (100)	217 (133-329)	Normal vs abnormal breathing pattern
Vonbank et al, ³⁴ 2021	Peer-reviewed published report	Prospective cohort	100	18/100 (18)	NR	Median, 112	Severity of acute infection

Abbreviations: ARDS, adult respiratory distress syndrome; DLCO, diffusion capacity of carbon monoxide; EHR, electronic health record; ICU, intensive care unit; LC, long COVID-19; mMRC, modified Medical Research Council Dyspnea Scale; NR, not reported; PASC, postacute sequelae of COVID-19; $\dot{V}O_2$, oxygen consumption.
^a Typically defined as the time from symptom onset or positive results of polymerase chain reaction testing, some studies used the date of admission or date of hospital discharge. Unless indicated otherwise, data are presented as mean (SD) or median (IQR). Pleguezuelos et al⁵⁶ reported time since hospital discharge and mean hospitalization of 23 days but not time from infection to hospitalization; therefore, it was unclear whether infection occurred more than 3 months previously. We identified an additional study by Ladlow et al⁶⁸; however, because it seemed likely that there were overlapping participants, we only included the main study.
^b Report on same prospective cohort study.

Table 2. Studies Reporting Peak Oxygen Consumption ($\dot{V}O_2$) Among Individuals With and Without Prevalent Symptoms Consistent With Long COVID-19 (LC) After SARS-CoV-2 Infection^a

Source	Definition of LC symptoms	Sex, No. (%)		Age, y	BMI	Hospitalized, No. (%)	Time after infection, d	Participants with LC symptoms		Participants with no LC symptoms			
		Female	Male					No.	Peak $\dot{V}O_2$, mL/kg/min	Peak $\dot{V}O_2$, % predicted	No.	Peak $\dot{V}O_2$, mL/kg/min	Peak $\dot{V}O_2$, % predicted
Aparisi et al, ⁴⁷ 2021	Persistent dyspnea vs no dyspnea	45 (64)	25 (36)	55 (12)	27 (5)	70 (100)	181 (42)	41	17.8 (15.8-21.2)	77.8 (64.0-92.5)	29	22.8 (18.8-27.7)	99 (88-105)
Barbagelata et al, ³⁸ 2022	Dyspnea or fatigue persisting >45 d after onset	98 (49)	102 (51)	49 (14)	26 (6)	39 (20)	80 (21)	112	25.8 (8.1)	89.7 (19.9)	88	28.8 (9.6)	92.9 (18.7)
Brown et al, ⁴⁴ 2022	Self-reported reduced exercise capacity	22 (55)	18 (45)	52	28	40 (100)	106	20	14.9 (13.1-16.2)	NR	20	19.1 (15.4-23.7)	NR
Durstenfeld et al, ²⁶ 2022	Chest pain, dyspnea, palpitations, or fatigue	18 (39)	28 (61)	52 (42-61)	30	7 (18)	526 (464-553)	23	21.2 (8.2)	89 (23)	16	28.8 (7.7)	111 (20)
Ladlow et al, ³¹ 2022	≥1 Symptom	13 (15)	74 (85)	39	29	35 (31)	159 (7)	61	32.4 (6.7)	NR	26	40.7 (8.9)	NR
Margalit et al, ³⁷ 2022	Fatigue	83 (59)	58 (41)	47 (13)	28 (5)	14 (14)	240 (75)	66	27.7 (7.5)	96.1 (18.3)	75	30.7 (7.5)	99.6 (17.4)
Schaeffer et al, ⁵⁸ 2022	Fatigue vs no fatigue	23 (47)	26 (53)	48	29	25 (40)	125 (16)	34	19.9 (7.1)	74 (20)	15	24.4 (6.7)	81 (17)
Sijðrten et al, ³³ 2021	Dyspnea, mMRC, 1-4 vs 0	60 (38)	96 (62)	56	28 (5)	156 (100)	104 (90-139)	59	23.6 (7.9)	NR	67	31.9 (9.3)	NR
Szekely et al, ²⁹ 2021	Persistent fatigue, dyspnea, muscle weakness, or pain	24 (34)	47 (66)	53 (16)	28 (6)	NR ^b	91 (26)	48	18.8 (6.3) and 1.5 (0.5) L/min	NR	23	21.3 (6.3) and 1.7 (0.5) L/min	NR

Abbreviations: BMI, body mass index (calculated as weight in kilograms divided by height in meters squared); mMRC, modified Medical Research Council Dyspnea Scale; NR, not reported.

^a Unless indicated otherwise, data are presented as mean (SD) or median (IQR). Cells with single values report the mean; SDs were only reported by subgroup.

^b All patients were evaluated in the emergency department, but the number or percentage admitted was not reported.

$\dot{V}O_2$ ⁶⁸ or by association between improvement in peak $\dot{V}O_2$ and symptoms²⁷ were excluded for not reporting peak $\dot{V}O_2$ by symptoms.

Clinical and methodologic variability likely contribute to heterogeneity. Clinical variability may result from the spectrum of LC severity and symptoms.⁷⁰ Most studies recruited before widespread vaccination, but 1 study²⁸ reported lower peak $\dot{V}O_2$ among unvaccinated compared with vaccinated individuals. In addition, methodologic variability in the definition of LC^{26,29} and CPET exercise modality (treadmill, upright cycle ergometer, or supine cycle ergometer) may also contribute. Most studies suggest higher acuity during acute infection (intensive care unit-treated vs hospitalized vs nonhospitalized patients) is associated with worse exercise capacity,³⁰⁻³⁴ although this is not a universal finding.^{35,36} Subgroup analyses by proportion hospitalized or time after SARS-CoV-2 infection were not significantly different compared with the overall result (eResults in the Supplement).


Residual confounding may also contribute to heterogeneity. Age, sex, body mass index, and prior fitness are highly associated with peak $\dot{V}O_2$ and likely associated with LC, but few studies addressed confounding. Margalit et al³⁷ reported that age, sex, pre-COVID-19 fitness, body mass index, and reduction in exercise time per week were similar among those with and without LC. Barbagaleta et al³⁸ adjusted for sex, cardiovascular history, use of β -blockers, and use of aspirin but not body mass index or age, and mean estimated peak $\dot{V}O_2$ was 3.2 (95% CI, 0.9-5.5) mL/min/kg lower in LC. Durstenfeld et al²⁶ estimated that mean peak $\dot{V}O_2$ was 5.9 (95% CI, 2.3-9.6) mL/kg/min lower in LC adjusted for age, sex, body mass index, time since infection, and hospitalization.

Patterns of Reduced Exercise Capacity

We included 37 studies with at least 714 people with reduced exercise capacity that classified patterns or limitations or investigated specific mechanisms (Table 3).^{26,27,29-31,33-66,68,69} Nearly all studies defined reduced exercise capacity as less than 80% or less than 85% of predicted levels. Approaches to CPET interpretation may differ, but few studies reported using specific guidelines or algorithms or their classification approach, so notable differences emerge between studies even with similar objective findings.

Deconditioning was reported as the most prevalent pattern by 10 studies,^{27,33,35,36,46,59,61-64} with alterations in muscular oxygen utilization acknowledged as an alternative explanation by some. Eight studies^{27,33,35,36,46,62-64} reporting deconditioning included mostly individuals hospitalized for severe acute COVID-19. Deconditioning may be more common among those hospitalized with other patterns (peripheral, ventilatory inefficiency) predominant among nonhospitalized patients.³¹ Muscular and/or peripheral oxygen extraction abnormalities were also commonly reported. Distinguishing deconditioning from altered oxygen delivery, mitochondrial dysfunction, muscular

Figure 2. Meta-analysis of Peak Oxygen Consumption ($\dot{V}O_2$) Among Studies Comparing Patients With and Without Long COVID-19 (LC) Symptoms



By random-effects meta-analysis of 9 studies that included 464 individuals with LC symptoms and 359 individuals without LC symptoms (as defined by each study), the mean difference in peak $\dot{V}O_2$ was -4.9 (95% CI, -6.4 to -3.4) mL/kg/min.

Table 3. Patterns of Limitations Among Individuals With Reduced Exercise Capacity More Than 3 Months After SARS-CoV-2 Infection

Source	Reduced exercise capacity, No. (%)	Pattern of limitations ^a						
		Deconditioning	Peripheral	Cardiac	Ventilatory	Chronotropic incompetence	Dysfunctional breathing and/or ventilatory inefficiency	Other mechanisms
Abdallah et al, ⁴⁵ 2021	41 (65)	Other identified	Other identified	NR	NR	Primary	NR	NR
Alba et al, ⁴² 2021	6 (33)	NA	Other identified	Other identified	Not identified	NR	NR	NR
Ambrosino et al, ⁵⁵ 2022	28 (78)	Other identified	Other identified	NR	NR	NR	Other identified	Endothelial dysfunction
Aparisi et al, ⁴⁷ 2021	NR	NR	NA	NR	NR	NR	Primary	NA
Barbagelata et al, ³⁸ 2022	39 (35)	NR	Other identified	Primary	Other identified	NR	NR	NR
Borrego Rodriguez et al, ⁵⁹ 2021	32 (56)	Primary	Other identified	NA	Not identified	NR	NR	NR
Brown et al, ⁴⁴ 2022	20 (50)	NR	Not identified	Primary	Not identified	NR	NR	Preload failure
Cassar et al, ²⁷ 2021	6 (19)	Primary	Other identified	Not identified	Not identified	NR	NR	Symptom limitation (submaximal tests)
Clavario et al, ⁶⁸ 2021	99 (50)	Other identified	Other identified	Other identified	Other identified	NR	NR	NR
de Boer et al, ⁴⁰ 2022	16 (32)	NR	Primary	Other identified	Not identified	NR	NR	Altered metabolism
Debeaumont et al, ³⁰ 2021	12 (52)	Other identified	NR	NR	Not identified	NR	Primary	NR
Dorelli et al, ⁴⁹ 2021	NR	NR	NR	NR	NR	NR	Primary	NR
Durstenfeld et al, ²⁶ 2022	15 (38)	Other identified	NA	Other identified	Not identified	Primary	NR	NR
Evers et al, ⁵⁴ 2022	11 (37)	NR	Primary	NR	NR	NR	NR	NR
Frédard et al, ⁵⁰ 2022	NR	NR	Other identified	NR	Primary (s)	NR	Primary (m)	NR
Godinho and Freeman, ⁶¹ 2021	5 (50)	Primary	Other identified	NR	Not identified	NR	NR	NR
Jahn et al, ⁶² 2021	19 (54)	Primary	NR	Other identified	Other identified	NR	NR	NR
Johnsen et al, ⁶³ 2021	16 (52)	Primary	NR	NR	Other identified	NR	NR	NR
Kersten et al, ⁵³ 2021	17 (55)	Other identified	NR	Other identified	Other identified	NR	NR	Pulmonary vascular
Ladlow et al, ³¹ 2022	4 (7)	Other identified (s)	Other identified (m)	NR	NR	NR	Other identified (m)	NR
Liu et al, ⁵² 2021	NR	NR	NR	NR	NR	NR	Other identified	Pulmonary fibrosis
Mancini et al, ⁴³ 2021	24 (59)	NR	Other identified	Other identified	Not identified	NR	Primary	Preload failure, pulmonary hypertension
Margalit et al, ³⁷ 2022	NR	NR	NR	NR	NR	Primary	NR	NR
Mohr et al, ⁴¹ 2021	8 (80)	NR	Primary	Other identified	Other identified	NR	NR	Critical illness polyneuropathy
Motiejunaite et al, ⁴⁶ 2021	86 (75)	Primary	NR	Not identified	Other identified	NR	Primary	"Lack of motivation" (submaximal tests)
Moulson et al, ⁵⁷ 2022	3 (14)	NR	NR	Not identified	Primary	Other identified	NR	Exertional hypotension
Parikes et al, ⁶⁴ 2021	10 (83)	Primary	NR	NR	Other identified	NR	Primary	Pulmonary vascular
Pleguezuelos et al, ⁵⁶ 2021	NR	NR	Primary	NR	NA	NR	NR	Mechanical inefficiency
Ribeiro Baptista et al, ³⁶ 2022	37 (35)	Primary	NR	Not identified	Other identified	NR	NR	NR
Rinaldo et al, ^{35,65} 2021	41 (55)	Primary	Other identified	NR	Not identified	NR	NR	NR
Singh et al, ³⁹ 2022	NR	NR	Primary	Not identified	NR	NR	Primary	NR
Sjøtten et al, ³³ 2021	49 (31)	Primary	NR	Other identified	Other identified	NR	Other identified	NR
Szekely et al, ²⁹ 2021	49 (69)	NA	Not identified	Other identified	Not identified	Primary	NR	Insufficient stroke volume increase
Vannini et al, ⁶⁶ 2021	19 (46)	Not identified	Not identified	Other identified	Other identified	NR	NR	NR
von Gruenewaldt et al, ⁵¹ 2022	2 (20)	NR	NR	NR	NR	NR	Primary	NR
Vonbank et al, ³⁴ 2021	NR	NR	Other identified	Other identified	Other identified	NR	NR	NR

Abbreviation: NA, not applicable; NR, not reported.

^a Designation (s) indicates a pattern noted among patients with severe acute illness; (m), a pattern noted among nonhospitalized patients with acute COVID-19.

pathology, and obesity can be challenging with noninvasive CPET without adjunctive testing or pre-COVID-19 CPET for comparison. Using invasive CPET, Singh et al³⁹ found reduced peripheral oxygen extraction, and others^{40,41} reported alterations in metabolism and lactate production. Importantly, none of the studies that included adjunctive cardiac imaging or right heart catheterization during exercise testing attributed their findings to deconditioning.^{29,39,42-44}

Cardiac limitations were uncommon, but studies with adjunctive cardiac testing identified reduced stroke volume augmentation that was likely attributable to preload failure^{29,43,44}; Singh et al³⁹ did not find evidence of preload failure. Five studies^{26,29,37,45,69} identified chronotropic incompetence as a contributor.

Although ventilatory limitations were uncommon, dysfunctional breathing, hyperventilation, or ventilatory inefficiency (V/Q mismatch) were commonly noted.^{43,46-51} One study each specifically reported dysautonomia,⁶⁹ pulmonary fibrosis,⁵² pulmonary vascular limitation,⁵³ impaired microcirculation,⁵⁴ endothelial dysfunction,⁵⁵ and loss of mechanical efficiency⁵⁶ as the primary cause of reduced exercise capacity. Despite concerns about pulmonary thromboembolism during acute infection, pulmonary vascular limitations were uncommon.

Longitudinal Trends

Four studies^{27,54,57,67} performed longitudinal CPET in a subset, including 1 interventional study. Cassar et al²⁷ reported CPET at 2 to 3 and at 6 months; median peak $\dot{V}O_2$ improved from 18.0 (IQR, 14.4-21.9) to 20.5 (IQR, 17.5-26.1) mL/kg/min but remained lower than that of controls (28.1 [95% CI, 22.1-34.0] mL/kg/min; $P \leq .001$ for all). Evers et al⁵⁴ found no change in peak $\dot{V}O_2$ during 3 months among 23 individuals with reduced exercise capacity who underwent repeated CPET (mean [SD] CPET 1: 86% [19%] of predicted levels; CPET 2: 85% [21%] of predicted levels; $P = .55$). Moulson et al⁵⁷ found improved peak $\dot{V}O_2$ among young symptomatic athletes 5 months after the index study, which correlated with symptom resolution. Barbara et al⁶⁷ found that mean (SD) peak $\dot{V}O_2$ improved from 17.8 (4.6) to 20.5 (4.5) mL/kg/min after 8 weeks of cardiac rehabilitation ($P < .001$).

Discussion

This meta-analysis and systematic review found 38 studies that reported CPET on 2160 individuals after SARS-CoV-2 infection, including 1228 with prevalent symptoms possibly consistent with LC and 714 with reduced exercise capacity. In our meta-analysis of symptomatic vs recovered individuals more than 3 months after SARS-CoV-2 infection, we found a modest but consistent effect suggesting that exercise capacity was reduced among individuals with LC, with very low certainty in the magnitude of the effect size by GRADE (eResults in the [Supplement](#)). Given the low certainty by GRADE, we identified classifications of exercise limitations without a single conclusive mechanism. Despite the large number of participants included, the overall quality of the evidence is poor owing to the small sample size of most studies, selection bias, variability in symptom ascertainment and CPET interpretation, inadequate methods to address confounding, and lack of appropriate statistical methods.

Challenges to Estimating the Association of LC With Exercise Capacity

Selection bias was a major challenge; the included studies oversampled hospitalized individuals with greater acute severity, more comorbidities, and lower baseline fitness. Hospitalization or need for intensive care during acute infection was associated with reduced peak $\dot{V}O_2$ and with LC,³⁰⁻³⁴ but most patients with LC were not hospitalized.⁷¹ Differential selection bias may occur among individuals who are hospitalized, are referred for clinical CPET, or attend CPET after joining a cohort, which may result in overestimation of the proportion of individuals with reduced exercise capacity.

Few studies addressed confounding; the most commonly used strategies included (1) reporting the percentage of predicted peak $\dot{V}O_2$ that implicitly adjusts for age, sex, height, and weight; (2) group matching on age, sex, and weight; and (3) excluding individuals with comorbid cardiac,

pulmonary, and musculoskeletal conditions. Preinfection fitness was an unmeasured confounder in all but 1 study³⁷; no studies had preinfection CPET to compare within-individual change. Two excluded studies among military recruits and professional athletes found reduced peak $\dot{V}O_2$ at 45 to 60 days after infection compared with before infection.^{72,73} A few studies used stepwise regression despite small sample sizes and colinear variables, resulting in exclusion of important confounders. Only 2 studies^{26,38} estimated an adjusted difference in peak $\dot{V}O_2$ between individuals with and without LC symptoms.

Using the GRADE framework, we have low confidence in our meta-analysis estimate of the difference in exercise capacity among individuals with and without LC symptoms. The included studies provided evidence of a clinically significant, mild to moderate decrease in exercise capacity among individuals with LC compared with infected individuals without LC symptoms despite different definitions of LC.

Insights Into Mechanisms of Reduced Exercise Capacity in LC

These studies should provide insight into mechanisms of LC, yet no consistent etiology of reduced exercise capacity has emerged, likely because of heterogeneity in inclusion criteria, variability in interpretation (measurement error), and the presence of multiple mechanisms of reduced exercise capacity in LC. Deconditioning, which occurs to some degree after any illness but especially during and after hospitalization, was commonly identified. On results of noninvasive CPET, peripheral mechanisms related to oxygen delivery and/or extraction due to muscular, mitochondrial, or vascular pathology can be misattributed to deconditioning. Use of invasive CPET, stress echocardiography, or stress magnetic resonance imaging allows for measurement or approximation of cardiac output, preload, pulmonary hypertension, and peripheral oxygen extraction and may therefore allow for more accurate classification. Overall, we found consistent evidence that deconditioning is not the only explanation of reduced exercise capacity in LC, especially among individuals who were not hospitalized.

Apart from peripheral mechanisms, other commonly reported patterns include (1) dysfunctional breathing or hyperventilation unexplained by baseline pulmonary function tests or findings on cross-sectional imaging, (2) chronotropic incompetence, and (3) preload failure despite normal resting cardiac function. Ventilatory, pulmonary vascular, and cardiac limitations are uncommon, suggesting that direct heart or lung damage (especially given other negative testing results) are not major drivers of exercise limitations in LC. From the diversity of interpretations, different phenotypes resulting in exertional intolerance seem more likely than a single unifying mechanism.

Autonomic dysfunction and endothelial dysfunction are possible mechanisms for these findings and could be caused by SARS-CoV-2 infection of neurons and endothelial cells, chronic inflammation, or autoimmune mechanisms. One included study found endothelial dysfunction⁵⁵ and 2 suggested dysautonomia^{37,69} to be associated with reduced exercise capacity in LC. Dysfunctional breathing may also be a manifestation of dysautonomia.⁶⁹ Autonomic nervous system and endothelial interaction may regulate peripheral vasomotor tone¹⁶; together, they may explain differences in peripheral extraction and preload failure. Small-fiber neuropathy among individuals who have LC symptoms with postural orthostatic tachycardia syndrome may be associated with reduced cerebral blood flow and postural symptoms.^{74,75} No published studies included comprehensive autonomic testing, endothelial testing, and CPET.

Comparison With ME/CFS

Myalgic encephalitis/chronic fatigue syndrome is associated with reduced peak $\dot{V}O_2$, lower ventilatory efficiency, higher perceived exertion, and lower peak heart rates,¹⁵ and chronotropic incompetence may contribute to exercise limitations.¹⁴ Alternatively, small-fiber neuropathy causing peripheral shunting reduces exercise capacity in ME/CFS.¹⁶ Postexertional malaise (PEM; recurrence or worsening of symptoms after exercise) has been reported in LC, similar to ME/CFS.^{76,77} The

overlap between ME/CFS and LC and whether LC has similar pathophysiology to ME/CFS remain unknown.

Recommendations for CPET for LC Clinical Care and Research

Given the heterogeneity of phenotypes of LC and lack of a single mechanism, CPET is clinically useful to narrow the differential diagnosis of exertional dyspnea in LC. A CPET result within reference range without cardiopulmonary limitations will reassure some individuals with LC and increase comfort with physical activity. For those with objective limitations, identifying a cardiac or ventilatory limitation could provide clues for further diagnostic testing and treatment. Risk of PEM should be considered in evaluation of the risk-benefit ratio of CPET among individuals reporting PEM.

With regard to research, determining the prevalence of exercise intolerance requires intentional sampling. Selection of control groups requires particular attention tailored to the research question. We recommend that CPET be performed as a maximal test that allows for assessment of chronotropy except for individuals with significant PEM, with adjunctive measures as per local expertise. Careful postexertional symptom assessment, including after CPET and 2-day CPET protocols, may provide insights into PEM in individuals with LC symptoms. Correlative data with autonomic testing may provide mechanistic insights. Given high reproducibility within individuals and reduced exercise capacity among individuals with LC symptoms, CPET may be a useful objective measure to include in interventional trials for potential LC therapeutics.

Limitations

This study has some limitations. The search plan was not peer reviewed, and the search was not limited to peer-reviewed studies. We may have missed studies that met our inclusion criteria, especially recent preprints. Many included studies were case series, which contributed only to classification of exercise limitations. Because of selection bias, we could not estimate the prevalence of reduced exercise capacity. There was moderate heterogeneity in the included studies. Additionally, we cannot rule out publication bias contributing to exaggeration of effect estimates, especially because 2 excluded studies did not find an association, although we mitigated this by including preprints and conference abstracts.

Conclusions

In this meta-analysis and systematic review, we found evidence that exercise capacity is reduced after SARS-CoV-2 infection among individuals who have symptoms consistent with LC, with a low confidence in the effect size. Further research should include longitudinal assessments to understand the trajectory of exercise capacity. Interventional trials of potential therapies are urgently needed, including studies of rehabilitation to address deconditioning, as well as further mechanistic investigation into dysfunctional breathing, autonomic dysfunction, chronotropic incompetence, impaired oxygen uptake or utilization, and preload failure to identify treatments for LC.

ARTICLE INFORMATION

Accepted for Publication: August 25, 2022.

Published: October 12, 2022. doi:10.1001/jamanetworkopen.2022.36057

Open Access: This is an open access article distributed under the terms of the [CC-BY License](#). © 2022 Durstenfeld MS et al. *JAMA Network Open*.

Corresponding Author: Matthew S. Durstenfeld, MD, MAS, Division of Cardiology, University of California, San Francisco at Zuckerberg San Francisco General Hospital, 1001 Potrero Ave, Room 5G8, San Francisco, CA 94110 (matthew.durstenfeld@ucsf.edu).

Author Affiliations: Department of Medicine, University of California, San Francisco (Durstenfeld, Sun, Peluso,

Deeks, Aras, Grandis, Long, Beatty, Hsue); Division of Cardiology, Zuckerberg San Francisco General Hospital, San Francisco, California (Durstensfeld, Hsue); UCSF Library, University of California, San Francisco (Tahir); Division of HIV, Infectious Diseases, and Global Medicine, Zuckerberg San Francisco General Hospital, University of California, San Francisco (Peluso, Deeks); Division of Cardiology, UCSF Health, University of California, San Francisco (Aras, Grandis, Long, Beatty); Department of Epidemiology and Biostatistics, University of California, San Francisco (Beatty).

Author Contributions: Dr Durstensfeld had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Durstensfeld, Sun, Peluso, Long, Hsue.

Acquisition, analysis, or interpretation of data: Durstensfeld, Tahir, Peluso, Deeks, Aras, Grandis, Beatty, Hsue.

Drafting of the manuscript: Durstensfeld, Sun, Tahir.

Critical revision of the manuscript for important intellectual content: Tahir, Peluso, Deeks, Aras, Grandis, Long, Beatty, Hsue.

Statistical analysis: Durstensfeld, Sun, Peluso.

Obtained funding: Durstensfeld, Peluso, Grandis, Long.

Administrative, technical, or material support: Durstensfeld, Tahir, Peluso, Deeks.

Supervision: Peluso, Aras, Grandis, Beatty, Hsue.

Conflict of Interest Disclosures: Dr Beatty reported receiving a salary in 2018 and 2019 and stock from 2019 to 2021 from Apple Inc and receiving grants from the National Heart, Lung, and Blood Institute (NHLBI) outside the submitted work. Dr Hsue reported receiving honoraria from Gilead Sciences Inc and Merck & Co Inc and receiving grants from Novartis AG outside the submitted work. No other disclosures were reported.

Funding/Support: This study was funded by grant K12 HL143961 from the NHLBI.

Role of the Funder/Sponsor: The sponsor had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

REFERENCES

1. Groff D, Sun A, Ssentongo AE, et al. Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. *JAMA Netw Open*. 2021;4(10):e2128568. doi:10.1001/jamanetworkopen.2021.28568
2. Hirschtick JL, Titus AR, Slocum E, et al. Population-based estimates of post-acute sequelae of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (PASC) prevalence and characteristics. *Clin Infect Dis*. 2021;73(11):2055-2064. doi:10.1093/cid/ciab408
3. Taquet M, Dercon Q, Luciano S, Geddes JR, Husain M, Harrison PJ. Incidence, co-occurrence, and evolution of long-COVID features: a 6-month retrospective cohort study of 273 618 survivors of COVID-19. *PLoS Med*. 2021;18(9):e1003773. doi:10.1371/journal.pmed.1003773
4. Office for National Statistics. Technical article: updated estimates of the prevalence of post-acute symptoms among people with coronavirus (COVID-19) in the UK: 26 April 2020 to 1 August 2021. September 16, 2021. Accessed April 29, 2022. <https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/technicalarticleupdatedestimatesoftheprevalenceofpostacutesymptomsamongpeoplewithcoronaviruscovid19intheuk/26april2020to1august2021>
5. Yomogida K, Zhu S, Rubino F, Figueroa W, Balanji N, Holman E. Post-acute sequelae of SARS-CoV-2 infection among adults aged ≥ 18 years—Long Beach, California, April 1-December 10, 2020. *MMWR Morb Mortal Wkly Rep*. 2021;70(37):1274-1277. doi:10.15585/mmwr.mm7037a2
6. Xie Y, Bowe B, Al-Aly Z. Burdens of post-acute sequelae of COVID-19 by severity of acute infection, demographics and health status. *Nat Commun*. 2021;12(1):6571. doi:10.1038/s41467-021-26513-3
7. Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. *Nat Med*. 2022;28(7):1461-1467. doi:10.1038/s41591-022-01840-0
8. Huang L, Yao Q, Gu X, et al. 1-Year outcomes in hospital survivors with COVID-19: a longitudinal cohort study. *Lancet*. 2021;398(10302):747-758. doi:10.1016/S0140-6736(21)01755-4
9. American Thoracic Society; American College of Chest Physicians. ATS/ACCP statement on cardiopulmonary exercise testing. *Am J Respir Crit Care Med*. 2003;167(2):211-277. doi:10.1164/rccm.167.2.211
10. Wasserman KHJ, Sue DY, Stringer W, Whipp BJ. *Principles of Exercise Testing and Interpretation*. 4th ed. Lippincott Williams and Wilkins; 2005.

11. Balady GJ, Arena R, Sietsema K, et al; American Heart Association Exercise, Cardiac Rehabilitation, and Prevention Committee of the Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Interdisciplinary Council on Quality of Care and Outcomes Research. Clinician's guide to cardiopulmonary exercise testing in adults: a scientific statement from the American Heart Association. *Circulation*. 2010;122(2):191-225. doi:10.1161/CIR.0b013e3181e52e69
12. Chan VL, Lam JY, Leung WS, Lin AW, Chu CM. Exercise limitation in survivors of severe acute respiratory syndrome (SARS). *Chest*. 2004;126(4):737S. doi:10.1378/chest.126.4_MeetingAbstracts.737S
13. Patterson AJ, Sarode A, Al-Kindi S, et al. Evaluation of dyspnea of unknown etiology in HIV patients with cardiopulmonary exercise testing and cardiovascular magnetic resonance imaging. *J Cardiovasc Magn Reson*. 2020;22(1):74. doi:10.1186/s12968-020-00664-6
14. Davenport TE, Lehnen M, Stevens SR, VanNess JM, Stevens J, Snell CR. Chronotropic intolerance: an overlooked determinant of symptoms and activity limitation in myalgic encephalomyelitis/chronic fatigue syndrome? *Front Pediatr*. 2019;7:82. doi:10.3389/fped.2019.00082
15. Cook DB, VanRiper S, Dougherty RJ, et al; MCAM Study Group. Cardiopulmonary, metabolic, and perceptual responses during exercise in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study. *PLoS One*. 2022;17(3):e0265315. doi:10.1371/journal.pone.0265315
16. Joseph P, Arevalo C, Oliveira RKF, et al. Insights from invasive cardiopulmonary exercise testing of patients with myalgic encephalomyelitis/chronic fatigue syndrome. *Chest*. 2021;160(2):642-651. doi:10.1016/j.chest.2021.01.082
17. Malhotra R, Bakken K, D'Elia E, Lewis GD. Cardiopulmonary exercise testing in heart failure. *JACC Heart Fail*. 2016;4(8):607-616. doi:10.1016/j.jchf.2016.03.022
18. Levett DZH, Jack S, Swart M, et al; Perioperative Exercise Testing and Training Society (POETTS). Perioperative cardiopulmonary exercise testing (CPET): consensus clinical guidelines on indications, organization, conduct, and physiological interpretation. *Br J Anaesth*. 2018;120(3):484-500. doi:10.1016/j.bja.2017.10.020
19. Baratto C, Caravita S, Faini A, et al. Impact of COVID-19 on exercise pathophysiology: a combined cardiopulmonary and echocardiographic exercise study. *J Appl Physiol (1985)*. 2021;130(5):1470-1478. doi:10.1152/jappphysiol.00710.2020
20. Arena R, Faghy MA. Cardiopulmonary exercise testing as a vital sign in patients recovering from COVID-19. *Expert Rev Cardiovasc Ther*. 2021;19(10):877-880. doi:10.1080/14779072.2021.1985466
21. Naeije R, Caravita S. Phenotyping long COVID. *Eur Respir J*. 2021;58(2):2101763. doi:10.1183/13993003.01763-2021
22. Soriano JB, Murthy S, Marshall JC, Relan P, Diaz JV; WHO Clinical Case Definition Working Group on Post-COVID-19 Condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. *Lancet Infect Dis*. 2022;22(4):e102-e107. doi:10.1016/S1473-3099(21)00703-9
23. Cochrane's Quality in Prognostic Studies tool. Accessed December 16, 2021. <http://methods.cochrane.org/sites/methods.cochrane.org/prognosis/files/uploads/QUIPS%20tool.pdf>
24. Balshem H, Helfand M, Schünemann HJ, et al. GRADE guidelines, 3: rating the quality of evidence. *J Clin Epidemiol*. 2011;64(4):401-406. doi:10.1016/j.jclinepi.2010.07.015
25. Higgins JPTLT, Deeks JJ. Choosing effect measures and computing estimates of effect. In: Higgins JPT, Thomas J, Chandler J, et al, eds. *Cochrane Handbook for Systematic Reviews of Interventions*. Version 6.3. Updated February 2022. Accessed May 12, 2022. <https://training.cochrane.org/handbook/PDF/v6.3>
26. Durstenfeld MS, Peluso MJ, Kaveti P, et al. Inflammation during early post-acute COVID-19 is associated with reduced exercise capacity and Long COVID symptoms after 1 year. *medRxiv*. Preprint posted online June 1, 2022. doi:10.1101/2022.05.17.22275235
27. Cassar MP, Tunnicliffe EM, Petousi N, et al. Symptom persistence despite improvement in cardiopulmonary health—insights from longitudinal CMR, CPET and lung function testing post-COVID-19. *EClinicalMedicine*. 2021;41:101159. doi:10.1016/j.eclinm.2021.101159
28. Blumberg Y, Edelstein M, Jabal KA, et al. Protective effect of BNT162b2 vaccination on aerobic capacity following mild to moderate SARS-CoV-2 infection: a cross sectional study, Israel, March-December 2021. *medRxiv*. Preprint posted online January 2, 2022. doi:10.1101/2021.12.30.21268538
29. Szekely Y, Lichter Y, Sadon S, et al. Cardiorespiratory abnormalities in patients recovering from coronavirus disease 2019. *J Am Soc Echocardiogr*. 2021;34(12):1273-1284.e9. doi:10.1016/j.echo.2021.08.022
30. Debeaumont D, Boujibar F, Ferrand-Devouge E, et al. Cardiopulmonary exercise testing to assess persistent symptoms at 6 months in people with COVID-19 who survived hospitalization: a pilot study. *Phys Ther*. 2021;101(6):pzab099. doi:10.1093/ptj/pzab099

31. Ladlow P, O'Sullivan O, Bennett AN, et al. The effect of medium-term recovery status after COVID-19 illness on cardiopulmonary exercise capacity in a physically active adult population. *J Appl Physiol (1985)*. 2022;132(6):1525-1535. doi:10.1152/jappphysiol.00138.2022
32. Romero-Ortuno R, Jennings G, Xue F, Duggan E, Gormley J, Monaghan A. Predictors of submaximal exercise test attainment in adults reporting long COVID symptoms. *J Clin Med*. 2022;11(9):2376. doi:10.3390/jcm11092376
33. Skjørten I, Ankerstjerne OAW, Trebinjac D, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. *Eur Respir J*. 2021;58(2):2100996. doi:10.1183/13993003.00996-2021
34. Vonbank K, Lehmann A, Bernitzky D, et al. Predictors of prolonged cardiopulmonary exercise impairment after COVID-19 infection: a prospective observational study. *Front Med (Lausanne)*. 2021;8:773788. doi:10.3389/fmed.2021.773788
35. Rinaldo RF, Mondoni M, Parazzini EM, et al. Severity does not impact on exercise capacity in COVID-19 survivors. *Respir Med*. 2021;187:106577. doi:10.1016/j.rmed.2021.106577
36. Ribeiro Baptista B, d'Humières T, Schlemmer F, et al. Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort. *Respir Res*. 2022;23(1):68. doi:10.1186/s12931-022-01977-z
37. Margalit I, Yelin D, Sagi M, et al. Risk factors and multidimensional assessment of long COVID fatigue: a nested case-control study. *Clin Infect Dis*. 2022;ciac283. doi:10.1093/cid/ciac283
38. Barbagelata L, Masson W, Iglesias D, et al. Cardiopulmonary exercise testing in patients with post-COVID-19 syndrome. *Med Clin (Engl Ed)*. 2022;159(1):6-11.
39. Singh I, Joseph P, Heerdt PM, et al. Persistent exertional intolerance after COVID-19: insights from invasive cardiopulmonary exercise testing. *Chest*. 2022;161(1):54-63. doi:10.1016/j.chest.2021.08.010
40. de Boer E, Petrache I, Goldstein NM, et al. Decreased fatty acid oxidation and altered lactate production during exercise in patients with post-acute COVID-19 syndrome. *Am J Respir Crit Care Med*. 2022;205(1):126-129. doi:10.1164/rccm.202108-1903LE
41. Mohr A, Dannerbeck L, Lange TJ, et al. Cardiopulmonary exercise pattern in patients with persistent dyspnoea after recovery from COVID-19. *Multidiscip Respir Med*. 2021;16(1):732. doi:10.4081/mrm.2021.732
42. Alba GA, Ziehr DR, Rouvina JN, et al. Exercise performance in patients with post-acute sequelae of SARS-CoV-2 infection compared to patients with unexplained dyspnea. *EClinicalMedicine*. 2021;39:101066. doi:10.1016/j.eclinm.2021.101066
43. Mancini DM, Brunjes DL, Lala A, Trivieri MG, Contreras JP, Natelson BH. Use of cardiopulmonary stress testing for patients with unexplained dyspnea post-coronavirus disease. *JACC Heart Fail*. 2021;9(12):927-937. doi:10.1016/j.jchf.2021.10.002
44. Brown JT, Saigal A, Karia N, et al. Ongoing exercise intolerance following COVID-19: a magnetic resonance-augmented cardiopulmonary exercise test study. *J Am Heart Assoc*. 2022;11(9):e024207. doi:10.1161/JAHA.121.024207
45. Abdallah SJ, Voduc N, Corrales-Medina VF, et al. Symptoms, pulmonary function, and functional capacity four months after COVID-19. *Ann Am Thorac Soc*. 2021;18(11):1912-1917. doi:10.1513/AnnalsATS.202012-1489RL
46. Motiejunaite J, Balagny P, Arnoult F, et al. Hyperventilation as one of the mechanisms of persistent dyspnoea in SARS-CoV-2 survivors. *Eur Respir J*. 2021;58(2):2101578. doi:10.1183/13993003.01578-2021
47. Aparisi Á, Ybarra-Falcón C, García-Gómez M, et al. Exercise ventilatory inefficiency in post-COVID-19 syndrome: insights from a prospective evaluation. *J Clin Med*. 2021;10(12):2591. doi:10.3390/jcm10122591
48. Crisafulli E, Dorelli G, Sartori G, Dalle Carbonare L. Exercise ventilatory inefficiency may be a relevant CPET-feature in COVID-19 survivors. *Int J Cardiol*. 2021;343:200. doi:10.1016/j.ijcard.2021.09.026
49. Dorelli G, Braggio M, Gabbiani D, et al; on behalf of the Respicovid Study Investigators. Importance of cardiopulmonary exercise testing amongst subjects recovering from COVID-19. *Diagnostics (Basel)*. 2021;11(3):507. doi:10.3390/diagnostics11030507
50. Frésard I, Genecand L, Altarelli M, et al. Dysfunctional breathing diagnosed by cardiopulmonary exercise testing in "long COVID" patients with persistent dyspnoea. *BMJ Open Respir Res*. 2022;9(1):e001126. doi:10.1136/bmjresp-2021-001126
51. von Gruenewaldt A, Nylander E, Hedman K. Classification and occurrence of an abnormal breathing pattern during cardiopulmonary exercise testing in subjects with persistent symptoms following COVID-19 disease. *Physiol Rep*. 2022;10(4):e15197. doi:10.14814/phy2.15197
52. Liu M, Lv F, Huang Y, Xiao K. Follow-up study of the chest CT characteristics of COVID-19 survivors seven months after recovery. *Front Med (Lausanne)*. 2021;8:636298. doi:10.3389/fmed.2021.636298

53. Kersten J, Baumhardt M, Hartveg P, et al. Long COVID: distinction between organ damage and deconditioning. *J Clin Med*. 2021;10(17):3782. doi:10.3390/jcm10173782
54. Evers G, Schulze AB, Osiaevi I, et al. Sustained impairment in cardiopulmonary exercise capacity testing in patients after COVID-19: a single center experience. *Can Respir J*. 2022;2022:2466789. doi:10.1155/2022/2466789
55. Ambrosino P, Parrella P, Formisano R, et al. Cardiopulmonary exercise performance and endothelial function in convalescent COVID-19 patients. *J Clin Med*. 2022;11(5):1452. doi:10.3390/jcm11051452
56. Pleguezuelos E, Del Carmen A, Llorensi G, et al. Severe loss of mechanical efficiency in COVID-19 patients. *J Cachexia Sarcopenia Muscle*. 2021;12(4):1056-1063. doi:10.1002/jcsm.12739
57. Moulson N, Gustus SK, Scirica C, et al. Diagnostic evaluation and cardiopulmonary exercise test findings in young athletes with persistent symptoms following COVID-19. *Br J Sports Med*. Published online May 18, 2022. doi:10.1136/bjsports-2021-105157
58. Schaeffer MR, Cowan J, Milne KM, et al. Cardiorespiratory physiology, exertional symptoms, and psychological burden in post-COVID-19 fatigue. *Respir Physiol Neurobiol*. 2022;302:103898. doi:10.1016/j.resp.2022.103898
59. Borrego Rodriguez J, Berenguel Senen A, De Cabo Porras C, et al. Cardiopulmonary exercise test in patients with persistent dyspnea after COVID-19 disease. *Eur Heart J*. 2021;42(suppl 1):ehab724.2675. doi:10.1093/eurheartj/ehab724.2675
60. Raman B, Cassar MP, Tunnicliffe EM, et al. Medium-term effects of SARS-CoV-2 infection on multiple vital organs, exercise capacity, cognition, quality of life and mental health, post-hospital discharge. *EClinicalMedicine*. 2021;31:100683. doi:10.1016/j.eclinm.2020.100683
61. Godinho L, Freeman A. Cardiopulmonary exercise testing to evaluate exercise limitation and shortness of breath in long COVID. *Thorax*. 2021;76(suppl 2):A19-A20.
62. Jahn K, Sava M, Sommer G, et al. Exercise capacity impairment after COVID-19 pneumonia is mainly caused by deconditioning. *Eur Respir J*. 2021;59(1):2101136. doi:10.1183/13993003.01136-2021
63. Johnsen S, Sattler SM, Miskowiak KW, et al. Descriptive analysis of long COVID sequelae identified in a multidisciplinary clinic serving hospitalised and non-hospitalised patients. *ERJ Open Res*. 2021;7(3):00205-02021. doi:10.1183/23120541.00205-2021
64. Parkes E, Shakespeare J, Robbins T, Kyrou I, Randeve H, Ali A. Utility of cardiopulmonary exercise testing (CPET) in the post-COVID-19 context: retrospective analysis of a single centre experience. *Research Square*. Preprint posted online May 25, 2021. doi:10.21203/rs.3.rs-537361/v1
65. Rinaldo RF, Mondoni M, Parazzini EM, et al. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. *Eur Respir J*. 2021;58(2):2100870. doi:10.1183/13993003.00870-2021
66. Vannini L, Quijada-Fumero A, Martín MPR, Pina NC, Afonso JSH. Cardiopulmonary exercise test with stress echocardiography in COVID-19 survivors at 6 months follow-up. *Eur J Intern Med*. 2021;94:101-104. doi:10.1016/j.ejim.2021.10.004
67. Barbara C, Clavario P, De Marzo V, et al. Effects of exercise rehabilitation in patients with long coronavirus disease 2019. *Eur J Prev Cardiol*. 2022;29(7):e258-e260. doi:10.1093/eurjpc/zwac019
68. Clavario P, De Marzo V, Lotti R, et al. Cardiopulmonary exercise testing in COVID-19 patients at 3 months follow-up. *Int J Cardiol*. 2021;340:113-118. doi:10.1016/j.ijcard.2021.07.033
69. Ladlow P, O'Sullivan O, Houston A, et al. Dysautonomia following COVID-19 is not associated with subjective limitations or symptoms but is associated with objective functional limitations. *Heart Rhythm*. 2022;19(4):613-620. doi:10.1016/j.hrthm.2021.12.005
70. Peluso MJ, Kelly JD, Lu S, et al. Persistence, magnitude, and patterns of postacute symptoms and quality of life following onset of SARS-CoV-2 infection: cohort description and approaches for measurement. *Open Forum Infect Dis*. 2021;9(2):ofab640. doi:10.1093/ofid/ofab640
71. Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. *Nat Med*. 2021;27(4):626-631. doi:10.1038/s41591-021-01292-y
72. Cramer GAG, Bielecki M, Züst R, Buehrer TW, Stanga Z, Deuel JW. Reduced maximal aerobic capacity after COVID-19 in young adult recruits, Switzerland, May 2020. *Euro Surveill*. 2020;25(36):2001542. doi:10.2807/1560-7917.ES.2020.25.36.2001542
73. Parpa K, Michaelides M. Aerobic capacity of professional soccer players before and after COVID-19 infection. *Sci Rep*. 2022;12(1):11850. doi:10.1038/s41598-022-16031-7
74. Novak P, Mukerji SS, Alabsi HS, et al. Multisystem involvement in post-acute sequelae of coronavirus disease 19. *Ann Neurol*. 2022;91(3):367-379. doi:10.1002/ana.26286

75. Oaklander AL, Mills AJ, Kelley M, et al. Peripheral neuropathy evaluations of patients with prolonged long COVID. *Neurol Neuroimmunol Neuroinflamm*. 2022;9(3):e1146. doi:10.1212/NXI.0000000000001146
76. Davis HE, Assaf GS, McCorkell L, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. *EClinicalMedicine*. 2021;38:101019. doi:10.1016/j.eclinm.2021.101019
77. Wright J, Astill SL, Sivan M. The relationship between physical activity and long COVID: a cross-sectional study. *Int J Environ Res Public Health*. 2022;19(9):5093. doi:10.3390/ijerph19095093

SUPPLEMENT.

eTable 1. Search Strategies for PubMed, Web of Science, and EMBASE

eTable 2. Quality Assessment and Potential Threats to Validity Among Studies Included in Comparison of Peak $\dot{V}O_2$ Among Those With and Without Symptoms >3 Months After SARS-CoV-2 Infection

eTable 3. Quality Assessment and Potential Threats to Validity Among Studies Included in Assessment of Limitations of Exercise Capacity

eMethods. Study Protocol

eAppendix. Study Findings and Quality Form

eResults. Sensitivity Analyses and GRADE Assessment

eFigure. Funnel Plot of Studies Comparing Peak $\dot{V}O_2$ Among People With and Without Symptoms